Upstream Bio, Inc. (UPB)
UPB Stock Price Chart
Explore Upstream Bio, Inc. interactive price chart. Choose custom timeframes to analyze UPB price movements and trends.
UPB Company Profile
Discover essential business fundamentals and corporate details for Upstream Bio, Inc. (UPB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Oct 2024
Employees
52.00
Website
https://upstreambio.comCEO
E. Rand Sutherland
Description
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
UPB Financial Timeline
Browse a chronological timeline of Upstream Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.78, while revenue estimate is $431.14k.
Earnings released on 13 May 2026
EPS came in at -$0.75 falling short of the estimated -$0.74 by -1.18%, while revenue for the quarter reached $1.03m , beating expectations by +0.62%.
Earnings released on 26 Mar 2026
EPS came in at -$0.79 falling short of the estimated -$0.73 by -8.22%, while revenue for the quarter reached $668.00k , beating expectations by +14.38%.
Earnings released on 5 Nov 2025
EPS came in at -$0.63 surpassing the estimated -$0.78 by +19.23%, while revenue for the quarter reached $683.00k , beating expectations by +30.95%.
Earnings released on 6 Aug 2025
EPS came in at -$0.74 falling short of the estimated -$0.61 by -21.31%, while revenue for the quarter reached $937.00k , beating expectations by +195.58%.
Earnings released on 6 May 2025
EPS came in at -$0.51 falling short of the estimated -$0.49 by -4.08%, while revenue for the quarter reached $566.00k , beating expectations by +78.55%.
Earnings released on 13 Mar 2025
EPS came in at -$1.59 falling short of the estimated -$0.56 by -183.93%, while revenue for the quarter reached $613.00k , beating expectations by +87.89%.
Earnings released on 7 Nov 2024
EPS came in at -$6.96 falling short of the estimated -$0.54 by -1.20k%, while revenue for the quarter reached $607.00k , beating expectations by +52.80%.
Earnings released on 11 Oct 2024
Earnings released on 31 Dec 2023
EPS came in at -$0.14 , while revenue for the quarter reached $2.38m .
Earnings released on 30 Sept 2023
EPS came in at -$0.09 , while revenue for the quarter reached $621.00k .
UPB Stock Performance
Access detailed UPB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
